CN102100833A - Drug composition for treating heart cerebrovascular diseases as well as preparation method and application thereof - Google Patents
Drug composition for treating heart cerebrovascular diseases as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN102100833A CN102100833A CN 201110025225 CN201110025225A CN102100833A CN 102100833 A CN102100833 A CN 102100833A CN 201110025225 CN201110025225 CN 201110025225 CN 201110025225 A CN201110025225 A CN 201110025225A CN 102100833 A CN102100833 A CN 102100833A
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- medicine
- bulbus allii
- rhizoma corydalis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a drug composition for treating heart cerebrovascular diseases, which is a preparation made from the raw medicines in parts by weight: 10-200 parts of pubescent holly root, 10-200 parts of corydalis tuber, 10-300 parts of snakegourd fruit, 10-200 parts of allium macrostemon and 10-200 parts of hawthorn leaves. The invention also provides a preparation method and application of the drug composition. The drug composition provided by the invention is used for treating the heart cerebrovascular diseases, has antithrombotic effect and clear treatment effect in particular aiming at cerebral thrombosis and brain tissue edema and is also used for treating arrhythmia and hypertension with an obvious treatment effect superior to a signal raw medicinal material; therefore, the invention provides a new drug selection for clinic.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease, belong to drug world.
Background technology
So-called cardiovascular and cerebrovascular disease is exactly cardiovascular and cerebrovascular disease general designation.Change along with growth in the living standard and rhythm of life, " three-hypers disease " (being hypertension, hyperglycemia and hyperlipidemia) that is called as " affluenza ", hypertensive old people uses depressor to be worthy of careful study, principle is arranged, selection for old depressor, with advancing age, the hypertension prevalence increases gradually.40%～45% suffer from hypertensive also suffer from simultaneously hyperglycemia or hyperlipidemia among the old people more than 60 years old, show according to Ministry of Public Health statistics in 2007, show that according to external data about 50% diabetes patient suffers from multiple infirmitiess of age such as hypertension, hyperlipidemia simultaneously.
Number of patent application: 200510034098.3, denomination of invention: a kind of Xinmaikang medicine Chinese medicine composition and preparation method thereof, the invention discloses a kind of Xinmaikang medicine Chinese medicine composition and preparation method thereof, it mainly by vinegar Rhizoma Corydalis, Rhizoma Chuanxiong, Rhizoma Curcumae Longae, Radix Ilicis Pubescentis, Herba Erigerontis, Pericarpium Trichosanthis, Bulbus Allii Macrostemonis, Borneolum Syntheticum eight flavor crude drug through distillation, water carry, alcohol extraction, drying and other steps make.This invention is to develop on the basis of clinical experience side; clinical practice for many years shows; this medicine is to alleviating coronary heart disease symptom; minimizing angina pectoris attacks number of times etc. has good result; it is stable that the study of pharmacy situation shows that this pharmaceutical worker plants; quality controllable, pharmacological toxicology studies show that, the effect that have obvious protection cardiac muscle, resists myocardial ischemia.
Chinese medicine has corresponding methods of treatment and corresponding dosage form at the characteristic of cardiovascular and cerebrovascular disease " chronic onset, acute attack, aftercare ", and the toxic and side effects less with respect to chemicals, Chinese medicine is more suitable for the cardiac and cerebral diseases long-term treatment and takes good care of.
Summary of the invention
Technical scheme of the present invention has provided a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease.Another technical scheme of the present invention has provided a kind of preparation of drug combination method and purposes for the treatment of cardiovascular and cerebrovascular disease.
The invention provides a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease, it is the preparation that is prepared from by following raw materials by weight proportions:
10～200 parts of Radix Ilicis Pubescentiss, 10～200 parts of Rhizoma Corydalis, 10～300 parts of Fructus Trichosanthis, 10～200 parts of Bulbus Allii Macrostemonis, 10～200 parts of Folium Crataegi.
Further preferably, the preparation that is prepared from by following raw materials by weight proportions:
120 parts of Radix Ilicis Pubescentiss, 100 parts of Rhizoma Corydalis, 150 parts of Fructus Trichosanthis, 100 parts of Bulbus Allii Macrostemonis, 100 parts of Folium Crataegi.
Pharmaceutical composition of the present invention is to be active component by the water of Radix Ilicis Pubescentis, Rhizoma Corydalis, Fructus Trichosanthis, Bulbus Allii Macrostemonis, Folium Crataegi or extractive with organic solvent, adds acceptable accessories or complementary composition and is prepared into preparation pharmaceutically commonly used.
Wherein, described preparation is tablet, capsule, granule, pill or oral liquid.
The present invention also provides a kind of method for preparing described pharmaceutical composition, and it comprises the steps:
A, take off and state materials of weight proportions: 10～200 parts of Radix Ilicis Pubescentiss, 10～200 parts of Rhizoma Corydalis, 10～300 parts of Fructus Trichosanthis, 10～200 parts of Bulbus Allii Macrostemonis, 10～200 parts of Folium Crataegi;
B, get Radix Ilicis Pubescentis and decoct with water, concentrate, add the 30-90% ethanol precipitation, filter, filtrate recycling ethanol is concentrated into the thick paste shape, and cold drying is ground into fine powder, and is standby;
C, get Fructus Trichosanthis, Bulbus Allii Macrostemonis, Rhizoma Corydalis, be ground into coarse powder, extract with 80% alcohol heating reflux, filter and get filtrate, filtrate decompression is condensed into thick paste, measures alkaloid, and is standby;
D, getting Folium Crataegi, be ground into coarse powder, is solvent with 30-90% ethanol, carries out percolation, collect percolate, decompression recycling ethanol, thin up adds petroleum ether and removes pigment, divide water-yielding stratum, extract with the ethyl acetate jolting, extracting solution reclaim under reduced pressure ethyl acetate and be concentrated into dried, total flavones;
E, the extract that b, c, d step are prepared mix, and add acceptable accessories or complementary composition and are prepared into preparation pharmaceutically commonly used.
The present invention also provides a kind of method for preparing described pharmaceutical composition, and it comprises the steps:
A, take off and state materials of weight proportions: 10～200 parts of Radix Ilicis Pubescentiss, 10～200 parts of Rhizoma Corydalis, 10～300 parts of Fructus Trichosanthis, 10～200 parts of Bulbus Allii Macrostemonis, 10～200 parts of Folium Crataegi;
B, get Radix Ilicis Pubescentis, Fructus Trichosanthis, Bulbus Allii Macrostemonis, Rhizoma Corydalis, be ground into coarse powder and decoct with water, filter, filtrate is condensed into thick paste, puts coldly, adds the 30-90% ethanol precipitation, filters and gets filtrate, reclaims ethanol, is concentrated into the thick paste shape, and cold drying is ground into fine powder, and is standby;
C, getting Folium Crataegi, be ground into coarse powder, is solvent with 30-90% ethanol, carries out percolation, collect percolate, decompression recycling ethanol, thin up adds petroleum ether and removes pigment, divide water-yielding stratum, extract with the ethyl acetate jolting, extracting solution reclaim under reduced pressure ethyl acetate and be concentrated into dried, total flavones;
D, the extract of getting the preparation of b, c step mix, and add acceptable accessories or complementary composition and are prepared into preparation pharmaceutically commonly used.
The present invention also provides a kind of method for preparing described pharmaceutical composition, and it comprises the steps:
A, take off and state materials of weight proportions: 10～200 parts of Radix Ilicis Pubescentiss, 10～200 parts of Rhizoma Corydalis, 10～300 parts of Fructus Trichosanthis, 10～200 parts of Bulbus Allii Macrostemonis, 10～200 parts of Folium Crataegi;
B, Folium Crataegi is become coarse powder with the Rhizoma Corydalis pulverize separately, getting Folium Crataegi coarse powder, fumitory coarse powder, Ilicis Purpureae, Fructus Trichosanthis, Bulbus Allii Macrostemonis again decocts with water, filter, filtrate is condensed into thick paste, puts cold, add the 30-90%v/v ethanol precipitation, filter, filtrate recycling ethanol is concentrated into the thick paste shape, cold drying adds acceptable accessories or complementary composition and is prepared into preparation pharmaceutically commonly used.
The present invention also provides the purposes of described compositions in the medicine of preparation treatment cardiovascular and cerebrovascular disease.
Wherein, described medicine is the medicine with anti thrombotic action.
Wherein, described medicine is anti-cerebral thrombosis, alleviates the bullate medicine of brain water that cerebral embolism causes.
Wherein, described medicine is treatment arrhythmia, hypertensive medicine.
Medicine of the present invention is used for the treatment of cardiovascular and cerebrovascular disease, has anti thrombotic action, especially at cerebral thrombosis, cerebral tissue edema, drug effect is clear and definite, also can be used for treating arrhythmia, hypertension, and drug effect obviously is better than single raw medicinal material, provides a kind of new medication to select for clinical.
The specific embodiment
The preparation method of embodiment 1 medicine of the present invention
Radix Ilicis Pubescentis 120g, Rhizoma Corydalis 100g, Fructus Trichosanthis 150g, Bulbus Allii Macrostemonis 100g, Folium Crataegi 100g
At first get Radix Ilicis Pubescentis and decoct with water twice, 4 hours for the first time, 2 hours for the second time, filter, merging filtrate, filtrate is condensed into thick paste, puts coldly, adds ethanol precipitation, filters, and filtrate recycling ethanol is concentrated into the thick paste shape, and cold drying is ground into fine powder, and is standby; Next gets Fructus Trichosanthis, Bulbus Allii Macrostemonis, Rhizoma Corydalis, is ground into coarse powder, extracts three times with 80% alcohol heating reflux, and each 4 hours, merge extractive liquid, filtered, and filtrate decompression is condensed into thick paste, measures alkaloid, and is standby; Get Folium Crataegi again, be ground into coarse powder, according to the percolation (appendix I O) under fluid extract and the extractum item, with ethanol is solvent, carry out percolation, collect percolate, decompression recycling ethanol is to finite concentration, after the water gaging dilution such as adding, add petroleum ether and remove pigment, divide water-yielding stratum, extract with the ethyl acetate jolting, extracting solution reclaim under reduced pressure ethyl acetate and be concentrated into dried, total flavones.Make preparation by said extracted thing mix homogeneously, promptly.
The preparation method of embodiment 2 medicines of the present invention
Radix Ilicis Pubescentis 120g, Rhizoma Corydalis 100g, Fructus Trichosanthis 150g, Bulbus Allii Macrostemonis 100g, Folium Crataegi 100g
At first get Radix Ilicis Pubescentis, Fructus Trichosanthis, Bulbus Allii Macrostemonis, Rhizoma Corydalis, be ground into coarse powder and decoct with water twice, 4 hours for the first time, 2 hours for the second time, filter merging filtrate, filtrate is condensed into thick paste, puts coldly, adds ethanol precipitation, filter, filtrate recycling ethanol is concentrated into the thick paste shape, cold drying, be ground into fine powder, standby; Next gets Folium Crataegi, is ground into coarse powder, according to the percolation (appendix I O) under fluid extract and the extractum item, with ethanol is solvent, carry out percolation, collect percolate, decompression recycling ethanol is to finite concentration, after the water gaging dilution such as adding, add petroleum ether and remove pigment, divide water-yielding stratum, extract with the ethyl acetate jolting, extracting solution reclaim under reduced pressure ethyl acetate and be concentrated into dried, total flavones.Make preparation by said extracted thing mix homogeneously, promptly.
The preparation method of embodiment 3 medicines of the present invention
Radix Ilicis Pubescentis 120g, Rhizoma Corydalis 100g, Fructus Trichosanthis 150g, Bulbus Allii Macrostemonis 100g, Folium Crataegi 100g
At first Folium Crataegi is become coarse powder with the Rhizoma Corydalis pulverize separately, get Folium Crataegi coarse powder, fumitory coarse powder, Ilicis Purpureae, Fructus Trichosanthis, Bulbus Allii Macrostemonis again and decoct with water twice, 4 hours for the first time, 2 hours for the second time, filter merging filtrate, filtrate is condensed into thick paste, puts coldly, adds ethanol precipitation, filter, filtrate recycling ethanol is concentrated into the thick paste shape, cold drying, capsule or other preparations are made in a kind of or any several combination that is ground in fine powder and starch or the adjuvants such as dextrin or lactose or sucrose, promptly.
The preparation of embodiment 4 medicines of the present invention
Get Radix Ilicis Pubescentis 10g, Rhizoma Corydalis 10g, Fructus Trichosanthis 10g, Bulbus Allii Macrostemonis 10g, Folium Crataegi 10g, press the method preparation of embodiment 1, mix, be prepared into granule.
The preparation of embodiment 5 medicines of the present invention
Get Radix Ilicis Pubescentis 200g, Rhizoma Corydalis 200g, Fructus Trichosanthis 300g, Bulbus Allii Macrostemonis 200g, Folium Crataegi 200g, press the method preparation of embodiment 2, mix, tabletting is prepared into tablet.
Below prove beneficial effect of the present invention by pharmacodynamics test
The test of pesticide effectiveness of experimental example 1 medicine of the present invention
1, experiment material
1,1 is subjected to reagent product and reagent
Medicine of the present invention (by embodiment 1 preparation), normal saline, and be made into 2%, 4%, 8% normal saline.XUESHUANXINMAINING capsule (Jilin Hua Kang pharmaceutcal corporation, Ltd).
1.2, animal
SD rat body weight 200～250g, male and female half and half, Cavia porcellus body weight 280～320g, Kunming mouse, body weight 20～25g.
Animal and feedstuff provide by Sichuan University's Experimental Animal Center.
1.3, experimental apparatus
560CA platelet polyphenyl instrument.Buy from the general bio tech ltd of last Heyman.
2, method and result
2.1 medicine of the present invention is to the influence of rat arteriovenous thrombosis
2.1.1 grouping administration: 50 SD rats are divided into 5 groups at random by body weight and sex equilibrium, XUESHUANXINMAINING capsule and other are organized equal gastric infusion, irritate gastric capacity and are every 100g body weight 1ml, every day 1 time, continuous 3d, 4d prepare before the experiment of arteriovenous loop thrombosis 1h administration 1 time again.1. the normal saline matched group is irritated stomach and is given normal saline; 2. the XUESHUANXINMAINING capsule is irritated stomach with 8% normal saline, and dosage is 0.4g/kgd
-13. the large, medium and small dosage group of medicine of the present invention gives 2%, 4%, 8% medicine of the present invention respectively, and dosage is respectively 0.2,0.4,0.8g/kgd
-1
2.1.2 preparation arteriovenous circulation thrombus model
Through the intraperitoneal anesthesia rat, separate right carotid and left side external jugular vein with 3% pentobarbital sodium (30mg/kg).The polyethylene tube that two heparin are handled inserts external jugular vein respectively, and heparin-saline (50u/ml) is full of polyethylene tube, and No. 4 long surgical threads of a 5cm are placed at two interface tube places.Then, open arterial-venous loop 15min, middle Herba Clinopodii takes out the thrombosis of parcel silk thread rapidly and weighs, and deducts silk thread weight, promptly gets wet weight of thrombus, and obtains its thrombosis suppression ratio.
2.1.3 result
With normal saline group wet weight of thrombus in contrast, carry out non-paired t test, the results are shown in Table 1.
Table 1 medicine of the present invention is to the influence of rat arteriovenous loop thrombosis
Studies show that the big or middle dosage (0.8g/kgd of medicine of the present invention
-1And 0.4g/kgd
-1) can obviously suppress the formation of rat arteriovenous loop thrombosis, wet weight of thrombus is reduced, illustrate that medicine of the present invention should have anti thrombotic action.
2.2 medicine of the present invention is to the effect of rat experiment cerebral thrombosis
2.2.1 medicine and reagent
Be subjected to the reagent product the same.Reagent: 1. thrombin: the brand-new auspicious Sheng in Chongqing City Biology Pharmacy Co., Ltd.2. adenosine diphosphate (ADP): Shanghai Vaccine and Serum Institute.3. adrenalin hydrochloride injection: Xi'an Lijun pharmaceutical Co., Ltd.4. acetone, Kingsoft, Chengdu chemical reagent factory produces.5. thrombosis derivant: be equipped with thrombosis derivant, ADP 1.25mmol/L in 100: 200: 5 ratios; Thrombin 1.25 ten thousand U/L; Adrenalin hydrochloride 1.0g/L.
2.2.2 grouping administration: rat is divided into 5 groups at random by body weight and sex equilibrium, and except that kinases intravenously administrable 1 time, other organizes equal gastric infusion, irritate gastric capacity and be every 100g body weight 1ml, every day 1 time, for three days on end, the administration 1 time again of preceding 1 hour of the 4th day preparation cerebral thrombosis model.1. model group is irritated stomach and is given normal saline; 2. XUESHUANXINMAINING Capsules group, dosage is 0.8g/kgd
-13. the large, medium and small dosage group of medicine of the present invention gives 2%, 4%, 8% medicine of the present invention respectively, and dosage is respectively 0.2,0.4,0.8g/kgd
-1(in primary crude drug).
2.2.3 preparation cerebral thrombosis model
With 3% pentobarbital sodium (30mg/kg) through the intraperitoneal anesthesia rat. separate endotracheal intubation; Separate right carotid, separate RECA forward along common carotid artery; Ligation external carotid artery and common carotid artery are entad held, standby from common carotid artery to the distal end intubate. every animal is injected Azo-Blue (0.2%) 5ml/kg by right common carotid artery after common carotid artery injects the every 100g body weight of thrombosis derivant 0.12ml 1.5min, rapid sacrificed by decapitation behind the 5min, open cranium and take out brain, separate right two hemispheres, it is heavy to take by weighing cutaneous horn. and then, cerebral tissue is put into homogenizer, add 0.5%Na
2SO
4And acetone (3: 7) mixed liquor 5ml, make homogenate, move into test tube sealing and standing 60min.Through the centrifugal 10min of 3000r/min, get supernatant, survey its optical density A value at the 620nm place.Represent the content of azovan blue with the optical density A value of thromboembolism hemisphere (the right survey serve as hard plug district, and it is the check plot that a left side is surveyed) and the ratio of its brain weight, represent the order of severity of cerebral thrombosis with this.With the ratio of infarct hemisphere weight with contrast left hemisphere weight, the degree of expression infraction side cerebral edema.Above-mentioned observation index is a contrast groups with the model group all, compares between organizing.
2.2.4 result
2.2.4.1 medicine of the present invention is to the influence of rat cerebral infarction district azovan blue content: the results are shown in Table 2.
Table 2 medicine of the present invention is to the influence of rat brain thrombosis azovan blue content
Studies show that, in the medicine of the present invention, heavy dose of (0.4,0.8g/kg/ days) can obviously reduce the azovan blue content of infraction hemisphere, illustrate that medicine of the present invention can alleviate the rat brain thrombosis, tangible experimental therapy effect is arranged, the XUESHUANXINMAINING capsule also has certain anti-cerebral thrombosis effect.
2.2.4.2 medicine of the present invention is to the influence of rat brain thrombosis the two cerebral hemispheres weight in wet base: the results are shown in Table 3
Table 3 pair rat cerebral infarction
All show with the model group comparative study, after the cerebral thrombosis model became, right cutaneous horn was heavy/and ratio that left cutaneous horn is heavy increases to some extent, and medicine heavy dose of the present invention can reduce the heavy ratio of right cutaneous horn, and show certain dose-effect relationship, illustrate that medicine of the present invention can alleviate the cerebral tissue edema that cerebral embolism rises.
2.3, Drug therapy arrhythmia of the present invention experiment
Use BaCl
2Bring out the rat ventricular experiment
100 of rats are divided into 10 groups at random, and promptly blank group (wait and hold distilled water), Chinese medicine medicine 0.8,0.4 of the present invention, 0.2g/kg organize positive control drug lignocaine 7mgkg
-1The group, the disposable gastric infusion of each administration group of medicine of the present invention, 1h after the administration, with rat with chloral hydrate (300mgkg
-1, the ip injection) and anesthesia, there are eight road physiology monitors to observe the II lead electrocardiogram, after waiting to stablize, trace, then in sublingual vein injection BaCl to electrocardiogram behind the medicine of the present invention
24mgkg
-1, trace injection BaCl immediately
2Electrocardiogram in the back 30min, electrocardiogram recovers normal number of animals in record arrhythmia persistent period and the 30min.The positive control treated animal is earlier with chloral hydrate anesthesia, then in sublingual vein injection lignocaine 7mgkg
-1, trace electrocardiogram after stablizing 15min, again sublingual vein injection BaCl
24mgkg
-1, all the other methods are the same.
Table 4 medicine of the present invention is to BaCl
2Bring out the influence of rat ventricular
Conclusion: rat intravenous injection BaCl
2After arrhythmia electrocardiograms such as two-phase tachycardia, ventricular premature contraction appear immediately, continue (29 ± 4.0) minute.And give medicine 0.8 of the present invention, 0.4gkg in advance
-1Or lignocaine 7mgkg
-1Can obviously alleviate the normal generation of the rhythm of the heart, the ARR persistent period is shortened, recover the number of rats of normal ECG in the 30min obviously more than BaCl
2Matched group illustrates that medicine of the present invention is to BaCl
2Institute's proarrhythmia has preventive effect preferably, and medicine promptly of the present invention can be treated the disease of arrhythmia aspect, and its arrhythmia effect of medicine of the present invention obviously is better than the single Chinese medicine extraction liquid under the Isodose.
2.4, to hypertensive influence
2.4.1 experiment material: rat blood pressure meter, hydrochlorothiazide tablet 5mg/ sheet, diazepam inj 2ml/ prop up, ketaject injection 2ml/ props up.
2.4.2 method
2.4.2.1 basic blood pressure is measured the quiet constant temperature (27 ℃) of measurement environment, measuring all rat arteria caudalis systolic pressures is basic blood pressure.
2.4.2.2 to rats by intraperitoneal injection 5% ketamine and each the 1mg/kg anesthesia of 0.5% diazepam, lie on the back, median abdominal incision, separate left renal artery by the sterile working, penetrate silk thread, the finer wire [finer wire diameter (mm)=rat body weight (g)/1000 ± 0.02] that to be close to the parallel placement diameter of renal artery be 0.2～0.3mm.Tighten renal artery and finer wire with silk thread, extract finer wire out.Sham operated rats is only opened the abdominal cavity, closes abdomen behind the separation left renal artery.Postoperative gives 2% sodium-chloride water solution, postoperative penicillin treatment (3 * 10 in 3 days
4U/d), pressure value 〉=30mmHg.
2.4.2.3 grouping and administration medicine of the present invention and hydrochlorothiazide experiment are that the basis is used for the animal effect experiment with the clinical equivalent amount all with dosage, medicine wherein of the present invention is in 0.2g/Kg, 0.4g/Kg, the administration of 0.8g/Kg body weight.Select for use the rat of pressure value 〉=30mmHg to divide 11 groups at random behind the operation 30d, every group 10, be respectively matched group (experimentation gives the equivalent distilled water), medicine high dose group of the present invention (0.8g/Kg), dosage group (0.4g/Kg) in the medicine of the present invention, medicine low dose group of the present invention (0.2g/Kg), hydrochlorothiazide group (25mg/kg), other has 10 of one group of sham operated rats.Each group is by above dosage gastric infusion 30d, and medicine low dose group of the present invention and Fructus Trichosanthis extracting solution group were each dead 1 when experiment finished.
2.4.2.4 the urine quantitative determination is measured the urine amount of all rats behind treatment 14d.Fasting 18h before the rat experiment, water is prohibited in fasting during experiment, collects the rat urine amount in the medication 6h.
2.4.2.5 blood pressure determination is measured all rat arteria caudalis systolic pressures after testing forward and backward 30d and medication 30d.
2.4.3 result
Experimental result sees Table 5:
Respectively organize before and after table 5 treatment rat arteria caudalis systolic pressure relatively (
Mm Hg)
Conclusion: the high, medium and low dosage group of treatment back medicine of the present invention, various single Chinese medicine extraction liquid group and hydrochlorothiazide group all can make blood pressure reduce, and compare with matched group, and highly significant difference is all arranged; Illustrate that medicine of the present invention is that obvious therapeutic action is arranged to hypertension, and medicine of the present invention is better than single Chinese medicine extraction liquid group under the same dose to the hypertension curative effect.
Claims (10)
1. pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease, it is characterized in that: it is the preparation that is prepared from by following raw materials by weight proportions:
10～200 parts of Radix Ilicis Pubescentiss, 10～200 parts of Rhizoma Corydalis, 10～300 parts of Fructus Trichosanthis, 10～200 parts of Bulbus Allii Macrostemonis, 10～200 parts of Folium Crataegi.
2. the pharmaceutical composition of treatment cardiovascular and cerebrovascular disease according to claim 1 is characterized in that: it is the preparation that is prepared from by following raw materials by weight proportions:
120 parts of Radix Ilicis Pubescentiss, 100 parts of Rhizoma Corydalis, 150 parts of Fructus Trichosanthis, 100 parts of Bulbus Allii Macrostemonis, 100 parts of Folium Crataegi.
3. pharmaceutical composition according to claim 1 and 2, it is characterized in that: it is to be active component by the water of Radix Ilicis Pubescentis, Rhizoma Corydalis, Fructus Trichosanthis, Bulbus Allii Macrostemonis, Folium Crataegi or extractive with organic solvent, adds acceptable accessories or complementary composition and is prepared into preparation pharmaceutically commonly used.
4. pharmaceutical composition according to claim 3 is characterized in that: described preparation is tablet, capsule, granule, pill or oral liquid.
5. method for preparing any described pharmaceutical composition of claim 1-4, it comprises the steps:
A, take off and state materials of weight proportions: 10～200 parts of Radix Ilicis Pubescentiss, 10～200 parts of Rhizoma Corydalis, 10～300 parts of Fructus Trichosanthis, 10～200 parts of Bulbus Allii Macrostemonis, 10～200 parts of Folium Crataegi;
B, get Radix Ilicis Pubescentis and decoct with water, concentrate, add the 30-90%v/v ethanol precipitation, filter, filtrate recycling ethanol is concentrated into the thick paste shape, and cold drying is ground into fine powder, and is standby;
C, get Fructus Trichosanthis, Bulbus Allii Macrostemonis, Rhizoma Corydalis, be ground into coarse powder, extract with the 80%v/v alcohol heating reflux, filter, filtrate decompression is condensed into thick paste, measures alkaloid, and is standby;
D, getting Folium Crataegi, be ground into coarse powder, is solvent with 30-90%v/v ethanol, carries out percolation, collect percolate, decompression recycling ethanol, thin up adds petroleum ether and removes pigment, divide water-yielding stratum, extract with the ethyl acetate jolting, extracting solution reclaim under reduced pressure ethyl acetate and be concentrated into dried, total flavones;
E, the extract that b, c, d step are prepared mix, and add acceptable accessories or complementary composition and are prepared into preparation pharmaceutically commonly used.
6. method for preparing any described pharmaceutical composition of claim 1-4, it comprises the steps:
A, take off and state materials of weight proportions: 10～200 parts of Radix Ilicis Pubescentiss, 10～200 parts of Rhizoma Corydalis, 10～300 parts of Fructus Trichosanthis, 10～200 parts of Bulbus Allii Macrostemonis, 10～200 parts of Folium Crataegi;
B, get Radix Ilicis Pubescentis, Fructus Trichosanthis, Bulbus Allii Macrostemonis, Rhizoma Corydalis, be ground into coarse powder and decoct with water, filter, filtrate is condensed into thick paste, puts coldly, adds the 30-90%v/v ethanol precipitation, filters, and filtrate recycling ethanol is concentrated into the thick paste shape, and cold drying is ground into fine powder, and is standby;
C, getting Folium Crataegi, be ground into coarse powder, is solvent with 30-90%v/v ethanol, carries out percolation, the collection liquid of filtering, decompression recycling ethanol, thin up adds petroleum ether and removes pigment, divide water-yielding stratum, extract with the ethyl acetate jolting, extracting solution reclaim under reduced pressure ethyl acetate and be concentrated into dried, total flavones;
D, the extract of getting the preparation of b, c step mix, and add acceptable accessories or complementary composition and are prepared into preparation pharmaceutically commonly used.
7. method for preparing any described pharmaceutical composition of claim 1-4, it comprises the steps:
A, take off and state materials of weight proportions: 10～200 parts of Radix Ilicis Pubescentiss, 10～200 parts of Rhizoma Corydalis, 10～300 parts of Fructus Trichosanthis, 10～200 parts of Bulbus Allii Macrostemonis, 10～200 parts of Folium Crataegi;
B, Folium Crataegi is become coarse powder with the Rhizoma Corydalis pulverize separately, getting Folium Crataegi coarse powder, fumitory coarse powder, Ilicis Purpureae, Fructus Trichosanthis, Bulbus Allii Macrostemonis again decocts with water, filter, filtrate is condensed into thick paste, puts cold, add the 30-90%v/v ethanol precipitation, filter, filtrate recycling ethanol is concentrated into the thick paste shape, cold drying adds acceptable accessories or complementary composition and is prepared into preparation pharmaceutically commonly used.
8. the purposes of any described compositions of claim 1-4 in the medicine of preparation treatment cardiovascular and cerebrovascular disease.
9. purposes according to claim 8 is characterized in that: described medicine is anti-cerebral thrombosis, alleviate cerebral tissue edema that cerebral embolism causes or treatment arrhythmia, hypertensive medicine.
10. any described compositions of claim 1-4 has purposes in the medicine of anti thrombotic action in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100252259A CN102100833B (en) | 2011-01-24 | 2011-01-24 | Drug composition for treating heart cerebrovascular diseases as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100252259A CN102100833B (en) | 2011-01-24 | 2011-01-24 | Drug composition for treating heart cerebrovascular diseases as well as preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102100833A true CN102100833A (en) | 2011-06-22 |
| CN102100833B CN102100833B (en) | 2012-02-29 |
Family
ID=44154033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100252259A Active CN102100833B (en) | 2011-01-24 | 2011-01-24 | Drug composition for treating heart cerebrovascular diseases as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102100833B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103908571A (en) * | 2013-01-08 | 2014-07-09 | 赵宪斌 | Compound traditional Chinese medicine preparation for treating heart disease |
| CN104510901A (en) * | 2013-10-08 | 2015-04-15 | 肖延斌 | Compound traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases |
| CN104510884A (en) * | 2013-10-08 | 2015-04-15 | 肖延斌 | Compound traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1853711A (en) * | 2005-04-18 | 2006-11-01 | 广州博济医药生物技术有限公司 | Xinmaikangzhong Chinese medicinal composition and preparation thereof |
-
2011
- 2011-01-24 CN CN2011100252259A patent/CN102100833B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1853711A (en) * | 2005-04-18 | 2006-11-01 | 广州博济医药生物技术有限公司 | Xinmaikangzhong Chinese medicinal composition and preparation thereof |
Non-Patent Citations (1)
| Title |
|---|
| 《中药材》 20091130 王廷春,等 心脉康胶囊对冠脉结扎模型犬急性心肌缺血的影响 1715-1719 1-10 第32卷, 第11期 2 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103908571A (en) * | 2013-01-08 | 2014-07-09 | 赵宪斌 | Compound traditional Chinese medicine preparation for treating heart disease |
| CN103908571B (en) * | 2013-01-08 | 2019-11-05 | 赵宪斌 | A kind of Chinese traditional compound medicine for treating heart disease |
| CN104510901A (en) * | 2013-10-08 | 2015-04-15 | 肖延斌 | Compound traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases |
| CN104510884A (en) * | 2013-10-08 | 2015-04-15 | 肖延斌 | Compound traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102100833B (en) | 2012-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1931236B (en) | Medicine composition of red sage and rhodiola root | |
| CN102048821B (en) | Method for preparing perhexiline pharmaceutical preparation | |
| CN101732668B (en) | Preparation method of Chinese medicinal composition for treating urinary system infection | |
| CN102100833B (en) | Drug composition for treating heart cerebrovascular diseases as well as preparation method and application thereof | |
| CN101428050B (en) | Active composition for treating thrombus, cardio-cerebrovascular system diseases | |
| CN102488838A (en) | Traditional Chinese medicine composition used for treating viral myocarditis | |
| CN102204956B (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| CN105920066A (en) | Applications, as well as preparation method and preparation of vernonia amygdalina extract | |
| CN102120000B (en) | Composition of effective parts of traditional Chinese medicine preparation for resisting Coxsackie virus B and preparation method thereof | |
| CN101152246B (en) | Pharmaceutical composition for cardiovascular and cerebrovascular diseases and method for preparing the same | |
| CN109512847A (en) | Plumbago zeylanica is in the purposes being used to prepare in treatment pulmonary fibrosis disease drug | |
| CN102319401A (en) | A kind of Chinese medicine composition that is used for benefiting QI for activating blood circulation, spleen invigorating collateral dredging and preparation method thereof | |
| CN102319399A (en) | Traditional Chinese medicine composition used for treating coronary heart disease and cerebral arteriosclerosis, and preparation method thereof | |
| CN101161268B (en) | Pharmaceutical composition of red sage root and cattail pollen | |
| CN101322762B (en) | Medicinal composition for treating diabetes | |
| CN107684601B (en) | Compound granule capable of reducing blood sugar and preparation method thereof | |
| CN105535890A (en) | Pharmaceutical composition for treating cardiovascular diseases and preparation method thereof | |
| CN100556435C (en) | The pharmaceutical composition of Radix Ginseng or Radix Ginseng Rubra, Radix Ophiopogonis and breviscapine | |
| CN102488728A (en) | Brain-soothing capsule for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN103830353A (en) | Pharmaceutical composition and application | |
| CN103550747B (en) | Composition for rescuing from collapse by restoring yang and preventing and curing chronic heart failure, medicament prepared from composition and preparation method of composition | |
| CN102670746B (en) | Anti-platelet activation traditional Chinese medicine composition for treating lupus erythematosus | |
| CN103405525A (en) | Composition and medicine for strengthening heart and preventing and curing chronic heart failure and preparation method | |
| CN107029026A (en) | A kind of Chinese medicine composition of inrigorating qi and promoting blood circulation | |
| CN102232997A (en) | Medicament for treating myocardial ischemia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Drug composition for treating heart cerebrovascular diseases as well as preparation method and application thereof Effective date of registration: 20181016 Granted publication date: 20120229 Pledgee: Luzhou Talents Innovation and entrepreneurship equity investment fund partnership (L.P.) Pledgor: SICHUAN GUOKANG PHARMACEUTICAL Co.,Ltd. Registration number: 2018510000103 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230525 Granted publication date: 20120229 Pledgee: Luzhou Talents Innovation and entrepreneurship equity investment fund partnership (L.P.) Pledgor: SICHUAN GUOKANG PHARMACEUTICAL Co.,Ltd. Registration number: 2018510000103 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |